Clinical Trial Update: Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT [Phase 1]

View source ↗

Summary

Phase 1 pilot study to detect PSMA-low castration-resistant prostate cancer with Fluciclovine PET/CT; trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer
• Prostate Neuroendocrine Carcinoma

Drugs mentioned

• Axumin (fluciclovine F-18) (fluciclovine F-18)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Advanced Prostate Cancer, Metastatic Prostate Cancer | Phase 1 | Status: RECRUITING